Clinical Trial Update: Korean Post-marketing Surveillance Vyndamax® Capsules for the Treatment of Transthyretin Amyloid Cardiomyopathy

View source ↗

Summary

A post-marketing surveillance study update for Vyndamax (tafamidis) in Korean patients with transthyretin amyloid cardiomyopathy shows the trial is currently ac…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Transthyretin Amyloid Cardiomyopathy

Drugs mentioned

• Vyndamax (tafamidis)

Snippet

Sponsor: Pfizer | Conditions: ATTR-CM (Transthyretin Amyloid Cardiomyopathy) | Status: ACTIVE_NOT_RECRUITING